Drugs / JANX011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07291323 | Feb → Oct 2026 expected | autoimmune disease | Janux Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | Janux Therapeutics | Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 januxrx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JANX011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07291323 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07291323 ↗ |